Literature DB >> 28196644

Re-evaluation of epidermodysplasia verruciformis: Reconciling more than 90 years of debate.

Joanna Przybyszewska1, Abraham Zlotogorski2, Yuval Ramot3.   

Abstract

Epidermodysplasia verruciformis (EV) is a rare genodermatosis characterized by abnormal susceptibility to cutaneous human beta-papillomavirus infections causing persistent flat warts or pityriasis versicolor-like lesions. This generalized verrucous skin disorder resembles generalized verrucosis, but these 2 conditions are distinguished by differences in clinical manifestation and the human papillomavirus types involved. A breakthrough in our understanding of EV was the discovery that homozygous inactivating mutations in TMC6 (EVER1) and TMC8 (EVER2) determine susceptibility to this disorder; however, they have not solved all EV cases fully. These deficiencies account for 75% of affected individuals, leaving a substantial number of patients without an underlying genetic cause. Recently, it has been revealed that mutations in additional genes (RHOH, MST-1, CORO1A, and IL-7) result in extensive human beta-papillomavirus replication and therefore manifest with an EV-like phenotype. The term "acquired EV" is used to describe an EV-like phenotype that develops in immunocompromised hosts, and the introduction of this entity further aggravates the confusion. Reevaluation of these entities is warranted. Here, we review the available data on this issue, provide up to date information on the major characteristics that differentiate between these seemingly clinically similar disorders, and highlight the different mechanisms involved in each disorder.
Copyright © 2016 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  EVER1; EVER2; SCID; epidermodysplasia verruciformis; general verrucosis; genetics; genodermatoses; human papillomavirus; immunodeficiency; squamous cell carcinoma

Mesh:

Year:  2017        PMID: 28196644     DOI: 10.1016/j.jaad.2016.12.035

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  10 in total

1.  Combined immunodeficiency with EBV positive B cell lymphoma and epidermodysplasia verruciformis due to a novel homozygous mutation in RASGRP1.

Authors:  Craig D Platt; Ari J Fried; Rodrigo Hoyos-Bachiloglu; G Naheed Usmani; Birgitta Schmidt; Jennifer Whangbo; Roberto Chiarle; Janet Chou; Raif S Geha
Journal:  Clin Immunol       Date:  2017-08-16       Impact factor: 3.969

2.  Inherited Interleukin 2-Inducible T-Cell (ITK) Kinase Deficiency in Siblings With Epidermodysplasia Verruciformis and Hodgkin Lymphoma.

Authors:  Leila Youssefian; Hassan Vahidnezhad; Mehdi Yousefi; Amir Hossein Saeidian; Arghavan Azizpour; Andrew Touati; Neda Nikbakht; Kambiz Kamyab- Hesari; Mohammad Mahdi Adib-Sereshki; Sirous Zeinali; Behzad Mansoori; Ali Jazayeri; Razieh Karamzadeh; Paolo Fortina; Emmanuelle Jouanguy; Jean-Laurent Casanova; Jouni Uitto
Journal:  Clin Infect Dis       Date:  2019-05-17       Impact factor: 9.079

3.  Epidermodysplasia Verruciformis and Breast Cancer - Casual or Causal?

Authors:  Trinidad Montero-Vilchez; Antonio Martinez-Lopez; Andrea Rodriguez-Tejero; Jesus Tercedor-Sanchez; Alejandro Molina-Leyva; Salvador Arias-Santiago
Journal:  Indian J Dermatol       Date:  2022 Jan-Feb       Impact factor: 1.757

4.  HPV-47-Induced and Tattoo-associated Verrucae Planae: Report of a Case and Review of the Literature.

Authors:  Nathalie Krecké; Sigrun Smola; Thomas Vogt; Cornelia Sigrid Lissi Müller
Journal:  Dermatol Ther (Heidelb)       Date:  2017-08-23

5.  Epidermodysplasia verruciformis in a young adult with activated PI3Kδ syndrome.

Authors:  Stephanie L Donaldson; J Chase Purnell; Peter G Pavlidakey; Thomas P Atkinson; Rebecca Kissel
Journal:  JAAD Case Rep       Date:  2019-01-31

6.  A novel EVER1 polymorphism of epidermodysplasia verruciformis: Homozygous TMC6 c.718del.

Authors:  Bret Kenny; Irina Oroz; Allison Osmond
Journal:  JAAD Case Rep       Date:  2022-01-21

7.  Nonpruritic hypopigmented macules on an immunocompromised patient.

Authors:  Karen Cravero; Michael Chung; Kiran Motaparthi; Sami K Saikaly
Journal:  JAAD Case Rep       Date:  2022-07-22

8.  An ANKRD26 nonsense somatic mutation in a female with epidermodysplasia verruciformis (Tree Man Syndrome).

Authors:  K M Furkan Uddin; Robed Amin; Sabbiha Nadia Majumder; Mohammad Abdul Aleem; Atikur Rahaman; Nushrat Jahan Dity; M D Abdul Baqui; Hosneara Akter; Muhammad Mizanur Rahman; Marc Woodbury-Smith; Stephen Scherer; Mohammed Uddin
Journal:  Clin Case Rep       Date:  2018-06-05

9.  Acquired epidermodysplasia verruciformis in setting of tumor necrosis factor-α inhibitor therapy.

Authors:  Brittney Schultz; Cuong V Nguyen; Erick Jacobson-Dunlop
Journal:  JAAD Case Rep       Date:  2018-09-14

Review 10.  Progress in L2-Based Prophylactic Vaccine Development for Protection against Diverse Human Papillomavirus Genotypes and Associated Diseases.

Authors:  Pola Olczak; Richard B S Roden
Journal:  Vaccines (Basel)       Date:  2020-10-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.